Quantitative study of mitochondrial complex I in platelets of parkinsonian patients.
Identifieur interne : 004524 ( PubMed/Curation ); précédent : 004523; suivant : 004525Quantitative study of mitochondrial complex I in platelets of parkinsonian patients.
Auteurs : F. Blandini [Italie] ; G. Nappi ; J T GreenamyreSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1998.
English descriptors
- KwdEn :
- 1-Methyl-4-phenylpyridinium (pharmacology), Aged, Aged, 80 and over, Blood Platelets (drug effects), Blood Platelets (enzymology), Case-Control Studies, Dopamine Agents (pharmacology), Dose-Response Relationship, Drug, Electron Transport Complex I, Female, Humans, Insecticides (metabolism), Male, Middle Aged, Mitochondria (drug effects), Mitochondria (enzymology), NADH, NADPH Oxidoreductases (blood), NADH, NADPH Oxidoreductases (metabolism), Neurotoxins (pharmacology), Parkinson Disease (blood), Parkinson Disease (enzymology), Radioligand Assay, Rotenone (analogs & derivatives), Rotenone (metabolism).
- MESH :
- chemical , analogs & derivatives : Rotenone.
- chemical , blood : NADH, NADPH Oxidoreductases.
- chemical , metabolism : Insecticides, NADH, NADPH Oxidoreductases, Rotenone.
- chemical , pharmacology : 1-Methyl-4-phenylpyridinium, Dopamine Agents, Neurotoxins.
- blood : Parkinson Disease.
- drug effects : Blood Platelets, Mitochondria.
- enzymology : Blood Platelets, Mitochondria, Parkinson Disease.
- Aged, Aged, 80 and over, Case-Control Studies, Dose-Response Relationship, Drug, Electron Transport Complex I, Female, Humans, Male, Middle Aged, Radioligand Assay.
Abstract
Activity of mitochondrial enzyme complex I (NADH-ubiquinone oxidoreductase) is reduced in the substantia nigra of patients with Parkinson's disease (PD). A less pronounced decrease in the activity of this enzyme has also been reported in platelets of PD patients. To obtain quantitative information on platelet complex I in PD, we studied platelet complex I in 16 PD patients and 16 age-matched controls by using a newly developed technique based on the binding of [3H]dihydrorotenone ([3H]DHR), an analog of the pesticide rotenone, to complex I. We also investigated the inhibitory effect of MPP+ (1-methyl-4-phenyl-pyridinium) on [3H]DHR specific binding to platelet complex I. PD patients and controls showed similar levels of [3H]DHR specific binding; preincubation of platelets with MPP+ caused the same degree of inhibition of [3H]DHR specific binding in the two groups. In PD patients, we observed a direct correlation between MPP+-induced inhibition of [3H]DHR specific binding and the daily intake of levodopa, which may be related to drug-induced changes in the transport of MPP+ into the platelet or in its binding to complex I. These findings demonstrate that the reported reduction in complex I activity in platelets of PD patients can not be accounted for by an abnormality at the level of the rotenone binding site (putatively the ND-1 gene product), although they do not exclude differences in complex I activity between PD patients and controls.
DOI: 10.1002/mds.870130106
PubMed: 9452319
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004524
Links to Exploration step
pubmed:9452319Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Quantitative study of mitochondrial complex I in platelets of parkinsonian patients.</title>
<author><name sortKey="Blandini, F" sort="Blandini, F" uniqKey="Blandini F" first="F" last="Blandini">F. Blandini</name>
<affiliation wicri:level="1"><nlm:affiliation>C. Mondino Neurological Institute, University of Pavia, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>C. Mondino Neurological Institute, University of Pavia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nappi, G" sort="Nappi, G" uniqKey="Nappi G" first="G" last="Nappi">G. Nappi</name>
</author>
<author><name sortKey="Greenamyre, J T" sort="Greenamyre, J T" uniqKey="Greenamyre J" first="J T" last="Greenamyre">J T Greenamyre</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1998">1998</date>
<idno type="RBID">pubmed:9452319</idno>
<idno type="pmid">9452319</idno>
<idno type="doi">10.1002/mds.870130106</idno>
<idno type="wicri:Area/PubMed/Corpus">004524</idno>
<idno type="wicri:Area/PubMed/Curation">004524</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Quantitative study of mitochondrial complex I in platelets of parkinsonian patients.</title>
<author><name sortKey="Blandini, F" sort="Blandini, F" uniqKey="Blandini F" first="F" last="Blandini">F. Blandini</name>
<affiliation wicri:level="1"><nlm:affiliation>C. Mondino Neurological Institute, University of Pavia, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>C. Mondino Neurological Institute, University of Pavia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nappi, G" sort="Nappi, G" uniqKey="Nappi G" first="G" last="Nappi">G. Nappi</name>
</author>
<author><name sortKey="Greenamyre, J T" sort="Greenamyre, J T" uniqKey="Greenamyre J" first="J T" last="Greenamyre">J T Greenamyre</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1998" type="published">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenylpyridinium (pharmacology)</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Blood Platelets (drug effects)</term>
<term>Blood Platelets (enzymology)</term>
<term>Case-Control Studies</term>
<term>Dopamine Agents (pharmacology)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Electron Transport Complex I</term>
<term>Female</term>
<term>Humans</term>
<term>Insecticides (metabolism)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Mitochondria (drug effects)</term>
<term>Mitochondria (enzymology)</term>
<term>NADH, NADPH Oxidoreductases (blood)</term>
<term>NADH, NADPH Oxidoreductases (metabolism)</term>
<term>Neurotoxins (pharmacology)</term>
<term>Parkinson Disease (blood)</term>
<term>Parkinson Disease (enzymology)</term>
<term>Radioligand Assay</term>
<term>Rotenone (analogs & derivatives)</term>
<term>Rotenone (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Rotenone</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>NADH, NADPH Oxidoreductases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Insecticides</term>
<term>NADH, NADPH Oxidoreductases</term>
<term>Rotenone</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>1-Methyl-4-phenylpyridinium</term>
<term>Dopamine Agents</term>
<term>Neurotoxins</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blood Platelets</term>
<term>Mitochondria</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Blood Platelets</term>
<term>Mitochondria</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Case-Control Studies</term>
<term>Dose-Response Relationship, Drug</term>
<term>Electron Transport Complex I</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Radioligand Assay</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Activity of mitochondrial enzyme complex I (NADH-ubiquinone oxidoreductase) is reduced in the substantia nigra of patients with Parkinson's disease (PD). A less pronounced decrease in the activity of this enzyme has also been reported in platelets of PD patients. To obtain quantitative information on platelet complex I in PD, we studied platelet complex I in 16 PD patients and 16 age-matched controls by using a newly developed technique based on the binding of [3H]dihydrorotenone ([3H]DHR), an analog of the pesticide rotenone, to complex I. We also investigated the inhibitory effect of MPP+ (1-methyl-4-phenyl-pyridinium) on [3H]DHR specific binding to platelet complex I. PD patients and controls showed similar levels of [3H]DHR specific binding; preincubation of platelets with MPP+ caused the same degree of inhibition of [3H]DHR specific binding in the two groups. In PD patients, we observed a direct correlation between MPP+-induced inhibition of [3H]DHR specific binding and the daily intake of levodopa, which may be related to drug-induced changes in the transport of MPP+ into the platelet or in its binding to complex I. These findings demonstrate that the reported reduction in complex I activity in platelets of PD patients can not be accounted for by an abnormality at the level of the rotenone binding site (putatively the ND-1 gene product), although they do not exclude differences in complex I activity between PD patients and controls.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9452319</PMID>
<DateCreated><Year>1998</Year>
<Month>03</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted><Year>1998</Year>
<Month>03</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>13</Volume>
<Issue>1</Issue>
<PubDate><Year>1998</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Quantitative study of mitochondrial complex I in platelets of parkinsonian patients.</ArticleTitle>
<Pagination><MedlinePgn>11-5</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Activity of mitochondrial enzyme complex I (NADH-ubiquinone oxidoreductase) is reduced in the substantia nigra of patients with Parkinson's disease (PD). A less pronounced decrease in the activity of this enzyme has also been reported in platelets of PD patients. To obtain quantitative information on platelet complex I in PD, we studied platelet complex I in 16 PD patients and 16 age-matched controls by using a newly developed technique based on the binding of [3H]dihydrorotenone ([3H]DHR), an analog of the pesticide rotenone, to complex I. We also investigated the inhibitory effect of MPP+ (1-methyl-4-phenyl-pyridinium) on [3H]DHR specific binding to platelet complex I. PD patients and controls showed similar levels of [3H]DHR specific binding; preincubation of platelets with MPP+ caused the same degree of inhibition of [3H]DHR specific binding in the two groups. In PD patients, we observed a direct correlation between MPP+-induced inhibition of [3H]DHR specific binding and the daily intake of levodopa, which may be related to drug-induced changes in the transport of MPP+ into the platelet or in its binding to complex I. These findings demonstrate that the reported reduction in complex I activity in platelets of PD patients can not be accounted for by an abnormality at the level of the rotenone binding site (putatively the ND-1 gene product), although they do not exclude differences in complex I activity between PD patients and controls.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blandini</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>C. Mondino Neurological Institute, University of Pavia, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nappi</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Greenamyre</LastName>
<ForeName>J T</ForeName>
<Initials>JT</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>NS33779</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>UNITED STATES</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007306">Insecticides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009498">Neurotoxins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>03L9OT429T</RegistryNumber>
<NameOfSubstance UI="D012402">Rotenone</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>6659-45-6</RegistryNumber>
<NameOfSubstance UI="C044985">1',2'-dihydrorotenone</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 1.6.-</RegistryNumber>
<NameOfSubstance UI="D009247">NADH, NADPH Oxidoreductases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 1.6.5.3</RegistryNumber>
<NameOfSubstance UI="D042967">Electron Transport Complex I</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>R865A5OY8J</RegistryNumber>
<NameOfSubstance UI="D015655">1-Methyl-4-phenylpyridinium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015655">1-Methyl-4-phenylpyridinium</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001792">Blood Platelets</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D015259">Dopamine Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D042967">Electron Transport Complex I</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007306">Insecticides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008928">Mitochondria</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009247">NADH, NADPH Oxidoreductases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009498">Neurotoxins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D011869">Radioligand Assay</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D012402">Rotenone</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs & derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year>
<Month>2</Month>
<Day>6</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1998</Year>
<Month>2</Month>
<Day>6</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1998</Year>
<Month>2</Month>
<Day>6</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">9452319</ArticleId>
<ArticleId IdType="doi">10.1002/mds.870130106</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004524 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 004524 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:9452319 |texte= Quantitative study of mitochondrial complex I in platelets of parkinsonian patients. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:9452319" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
This area was generated with Dilib version V0.6.23. |